Accredited Investors Employee Shareholders Institutions Private Companies Who We Serve Trading and InvestingData SolutionsPrivate Asset Custody Institutional TradingForge ProTrade private companies with Forge’s institutional brokerage toolBrowse CompaniesIndividual InvestingForge MarketsFind new private company investment opportunitiesForge DataAnalyze private markets via Forge’s intuitive web applicationForge Private Market IndexMonitor a benchmark for actively traded private companies Forge Accuidity Private Market IndexInvest in an institutionally-managed diversified basket of private companies (QPs only)Self-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRASolutions All InsightsPrivate Market ReportsMarket InsightsBuying and Selling Pre-IPO All ReportsPrivate Market Updates Forge Investment OutlookStartup News and TrendsPrivate Market Data and AnalyticsTech IPO Calendar for 2024Private Market ExplainedBuying Pre-IPO SharesSelling Pre-IPO Shares Glossary Videos FAQsInsights About Us Leadership Investor Relations People & Culture Careers About

BioAge Stock

Q: How to sell BioAge stock?

If you hold private company shares of BioAge - whether as an employee or an early investor - Forge can help you sell them. 1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have. 2. Indicate your interest to sell your BioAge stock on our platform. 3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.

bioagelabs.comHealthcare / BioTech & PharmaFounded: 2015Funding to Date: $321.26MM

BioAge develops a pipeline of treatments to extend healthy lifespan by targeting the molecular causes of aging by using its discovery platform, which combines quantitative analysis of proprietary longitudinal human samples with detailed health records tracking individuals over the lifespan, to map out the key molecular pathways that impact healthy human aging.

Buy or sell BioAge stockLearn more about BioAge IPO

OverviewFinancingsValuation

Enterprise Value

Access BioAge’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like BioAge.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Access Stock Price

Animation displayed is not current and securities are shown for illustrative purposes only.

BioAge investors also invested in these private companies

Redpoint Ventures

Mistral AI, Stripe, Arctic Wolf, PsiQ, Whatnot, Wealthsimple, Cribl, FloQast, BioAge, BitGo

Andreessen Horowitz

Wiz, xAI, Anduril, KoBold Metals, Databricks, Zipline, Waymo, Mistral AI, Ripple, Shield AI

Khosla Ventures

OpenAI, Waabi, Natron, Stripe, Synchron, Indiegogo, Hermeus, Ramp, Eat Just, Impossible Foods

Ra Capital Management

X-energy, Element Biosciences, Mindtickle, BioAge, Freenome, Capstan Therapeutics, Synthego, Sionna Therapeutics, FogPharma, Bicara Therapeutics

AME Cloud Ventures

Eat Just, Cohere Technologies, Mojo Vision, Mythic, Illumio, Vectra AI, BitPay, BioAge, Docker, Freenome

Longitude Capital

BioAge, Zenas BioPharma, Quanta Therapeutics, Dascena, Nalu, Nalu Medical, Cohere Health, Endeavor BioMedicines

Caffeinated Capital

Notion, Vercel, Bolt Financial, Brex, Mercury, Hadrian, Forward, BioAge, Loft, SingleStore (MemSQL)

Bossanova Investimentos

SpinLaunch, Axiom Space, Bending Spoons, Plume, BioAge, Petal, Hotmart, JumpCloud, Xage, Wright

Felicis

Crusoe, Canva, Credit Karma, Gusto, Runway, Skild AI, Formation Bio, Guideline, Crunchbase, Weights & Biases

Cormorant Asset Management

BioAge, Aardvark Therapeutics, Myra Vision, Alumis, FogPharma, Orionis Biosciences, Neurona Therapeutics, Ensoma, Supira Medical, Bigfoot Biomedical

Pear VC

BioAge, Branch Metrics, Nightfall AI, One Concern, Guardrails AI

Green Sands Equity

USA Rare Earth, Synchron, Fizz, Pasqal, Devoted Health, BioAge, Commure

Sofinnova Investments

BioAge, Capstan Therapeutics, Chroma Medicine, Quanta Therapeutics, Seaport Therapeutics, Antiva Biosciences, OnCusp Therapeutics, RayzeBio, Avenzo, Star Therapeutics

RTW Investments

Beta Bionics, BioAge, Santa Ana Bio, Obsidian Therapeutics, Acelyrin, Lycia Therapeutics, Apogee Therapeutics, Mineralys

Sands Capital

StockX, Ramp, BioAge, Upgrade, Klaviyo, Freenome, Globalization Partners, OneTrust, Primer, CytoVale

Osage University Partners

Brimstone, Menlo Security, Corelight, BioAge, Censys, Chroma Medicine, Delfi Diagnostics, Verve Motion, Quantum Circuits

OrbiMed

ADARx Pharmaceuticals, Carrot, BioAge, Insilico Medicine, Capstan Therapeutics, Caris Life Sciences, Delfi Diagnostics, Sionna Therapeutics, Scorpion Therapeutics, Iambic Therapeutics

Summit Peak Investments

Rippling, Notion, Navan, BioAge, SingleStore (MemSQL), Virta Health, Route, AgentSync, Two Chairs, Peregrine

CSC UpShot Ventures

Triller, Rippling, Notion, Tala, Gecko Robotics, Nav, Side, Maven, Kin Insurance, BioAge

Pivotal bioVenture Partners

BioAge, Zenas BioPharma, Evommune

Summer VC

OURA, BioAge, Parsley Health

Amgen

Quantinuum, BioAge, Generate Biomedicines, Carmot Therapeutics, Casma Therapeutics, Hummingbird Bioscience, Obsidian Therapeutics

AARP Foundation

BioAge, XRHealth

Springboard Enterprises

BioAge

Team

Management Team

Kristen Fortney Ph.D

Co-Founder & Chief Executive Officer

Eric Morgen MD

Co-Founder & Chief Operating Officer

BJ Sullivan Ph.D

Chief Strategy Officer

Ann Neale

Chief Development Officer

Peng Leong Ph.D

Chief Business Officer & Therapeutic Area Head, Brain Aging

Paul Rubin MD

Chief Medical Officer & Executive Vice President of Research

Dov Goldstein MD

Chief Financial Officer

Board Members

James Healy Ph.D

Sofinnova Investments

Vijay Pande Ph.D

Andreessen Horowitz

BioAge stock FAQs

Can you buy BioAge stock?

As BioAge is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private company like BioAge, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not an accredited investor, discover how to begin the process to potentially qualify for new investment opportunities.

How to buy BioAge stock?

To invest in a private company like BioAge through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

Create a free account to access Forge’s marketplace.
Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.

Can you sell BioAge stock?

Yes, you may be able to sell your BioAge stock, subject to certain conditions. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company's interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.

How to sell BioAge stock?

If you hold private company shares of - whether as an employee or an early investor - Forge can help you sell them.

Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
Indicate your interest to sell your BioAge stock on our platform.
Work with your dedicated Private Market Specialist who'll help guide you through every step of the transaction.

Is BioAge a public company?

No, BioAge is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.

What is BioAge’s stock price?

BioAge is a privately held company and therefore does not have a public stock price. However, you may access BioAge’s private market stock price with Forge Data.

What is BioAge’s stock ticker symbol?

BioAge does not have an official ticker symbol because this company is not currently publicly traded.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Fierce Biotech 02/13/2024

GLP-1 enthusiasm pushes BioAge Labs into new age with $170M series D

Until last year, BioAge Labs' progress could be best described as a slow burn, with a pipeline of longevity-focused medicines taking shape incrementally but consistently. The frenzy around GLP-1s changed all of that, with BioAge’s profile ascending dramatically thanks to being one of a select few biotechs with a combo candidate that might enhance weight loss without muscle loss. Equipped with that potential, and a partnership with Eli Lilly to test the hypothesis, BioAge has closed a $170 million series D led by Sofinnova with contributions from major institutional biotech investors and the venture arms of both the Indianapolis pharma and Amgen.

Reuters 02/13/2024

Eli Lilly partner BioAge raises $170 mln for obesity treatment

BioAge Labs, a biotech startup collaborating with Eli Lilly (LLY.N), opens new tab for trialing its obesity therapy, said on Tuesday it had raised $170 million in its latest funding round.

Browse More Insights

Frequently Asked Questions

Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.